Cartesian Therapeutics (RNAC) Stock Forecast & Price Target

Compare

1,136 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RNAC Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Cartesian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RNAC Stock 12 Month Forecast

Average Price Target

$34.67

▲(380.19% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Cartesian Therapeutics in the last 3 months. The average price target is $34.67 with a high forecast of $44.00 and a low forecast of $16.00. The average price target represents a 380.19% change from the last price of $7.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","45":"$45","15.75":"$15.75","25.5":"$25.5","35.25":"$35.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.75,25.5,35.25,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,10.123076923076923,12.946153846153846,15.76923076923077,18.592307692307692,21.415384615384617,24.23846153846154,27.061538461538465,29.884615384615387,32.707692307692305,35.53076923076923,38.353846153846156,41.176923076923075,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,9.405384615384616,11.510769230769231,13.616153846153846,15.721538461538461,17.826923076923077,19.932307692307695,22.03769230769231,24.143076923076926,26.24846153846154,28.353846153846156,30.45923076923077,32.56461538461539,{"y":34.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,7.969230769230769,8.638461538461538,9.307692307692307,9.976923076923077,10.646153846153846,11.315384615384616,11.984615384615385,12.653846153846153,13.323076923076922,13.99230769230769,14.661538461538461,15.330769230769231,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$44.00

Average Price Target$34.67

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gil Blum

Needham

$40

Buy

454.02%

Upside

Reiterated

12/12/25

Strategic Positioning and Unique Treatment Profile Drive Buy Rating for Cartesian TherapeuticsWe recently hosted Cartesian's management for virtual investor meetings. In this note, we highlight some of the most frequently discussed questions and topics. Our key takeaways are as follows: with Vyvgart. Investors wanted to understand the differences Descartes-08 offers. Cartesian pointed to an emerging TPP with (at most) an annual administration rate contrasted with chronic administration for Vyvgart.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/21/25

Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian TherapeuticsWe believe this was the right decision, especially as the company plans to move Descartes-08 into myositis instead, where competition is less and there are more similarities to the lead MG indication. ...And the strong results observed in SLE and gMG, Cartesian plans to move Descartes-08 forward in the second potentially pivotal trial in myositis patients. Management believes that this is a derisked indications given the significant decreases observed in plasmacytoid dendritic cells (pDCs) at 3 months in both gMG and SLE, which is a biomarker with a high correlation to myositis.

Mitchell Kapoor

H.C. Wainwright

$40→$30

Buy

315.51%

Upside

Reiterated

11/19/25

H.C. Wainwright cuts Cartesian target, calls shares 'mispriced'H.C. Wainwright cuts Cartesian target, calls shares 'mispriced'

Julian Harrison

BTIG

$42→$44

Buy

509.42%

Upside

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Athira Pharma (NASDAQ: ATHA) and Cartesian Therapeutics (NASDAQ: RNAC)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (NASDAQ: RNAC) and Galmed Pharmaceuticals (NASDAQ: GLMD)

Martin Fan

Wedbush

$38

Buy

426.32%

Upside

Reiterated

11/14/25

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

Kristen Kluska

Cantor Fitzgerald

$16

Hold

121.61%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Uy Ear

Mizuho Securities

$40

Buy

454.02%

Upside

Reiterated

11/06/25

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

Thomas Smith

Leerink Partners

$39

Buy

440.17%

Upside

Reiterated

08/11/25

Cartesian Therapeutics (RNAC) Receives a Buy from Leerink Partners

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gil Blum

Needham

$40

Buy

454.02%

Upside

Reiterated

12/12/25

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/21/25

Mitchell Kapoor

H.C. Wainwright

$40→$30

Buy

315.51%

Upside

Reiterated

11/19/25

H.C. Wainwright cuts Cartesian target, calls shares 'mispriced'H.C. Wainwright cuts Cartesian target, calls shares 'mispriced'

Julian Harrison

BTIG

$42→$44

Buy

509.42%

Upside

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Athira Pharma (NASDAQ: ATHA) and Cartesian Therapeutics (NASDAQ: RNAC)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/14/25

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (NASDAQ: RNAC) and Galmed Pharmaceuticals (NASDAQ: GLMD)

Martin Fan

Wedbush

$38

Buy

426.32%

Upside

Reiterated

11/14/25

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

Kristen Kluska

Cantor Fitzgerald

$16

Hold

121.61%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Uy Ear

Mizuho Securities

$40

Buy

454.02%

Upside

Reiterated

11/06/25

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

Thomas Smith

Leerink Partners

$39

Buy

440.17%

Upside

Reiterated

08/11/25

Cartesian Therapeutics (RNAC) Receives a Buy from Leerink Partners

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cartesian Therapeutics

1 Month

xxx

Success Rate

7/13 ratings generated profit

Average Return

+6.41%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +6.41% per trade.

3 Months

xxx

Success Rate

7/16 ratings generated profit

Average Return

+2.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +2.14% per trade.

1 Year

Gil BlumNeedham

Success Rate

3/22 ratings generated profit

Average Return

-30.09%

reiterated a buy rating 9 days ago

Copying Gil Blum's trades and holding each position for 1 Year would result in 13.64% of your transactions generating a profit, with an average return of -30.09% per trade.

2 Years

xxx

Success Rate

1/16 ratings generated profit

Average Return

-48.66%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 6.25% of your transactions generating a profit, with an average return of -48.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNAC Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RNAC has received 8 Buy Ratings, 5 Hold Ratings, and 4 Sell Ratings. RNAC average Analyst price target in the past 3 months is 34.67.

Each month's total comprises the sum of three months' worth of ratings.

RNAC Financial Forecast

RNAC Earnings Forecast

Next quarter’s earnings estimate for RNAC is -$0.83 with a range of -$1.13 to -$0.76. The previous quarter’s EPS was -$1.38. RNAC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.

RNAC Sales Forecast

Next quarter’s sales forecast for RNAC is $150.00K with a range of $0.00 to $452.00K. The previous quarter’s sales results were $452.00K. RNAC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RNAC has Performed in-line its overall industry.

RNAC Stock Forecast FAQ

What is RNAC’s average 12-month price target, according to analysts?

Based on analyst ratings, Cartesian Therapeutics’s 12-month average price target is 34.67.

What is RNAC’s upside potential, based on the analysts’ average price target?

Cartesian Therapeutics has 380.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RNAC a Buy, Sell or Hold?

Cartesian Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cartesian Therapeutics’s price target?

The average price target for Cartesian Therapeutics is 34.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $44.00 ,the lowest forecast is $16.00. The average price target represents 380.19% Increase from the current price of $7.22.

What do analysts say about Cartesian Therapeutics?

Cartesian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of RNAC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cartesian Therapeutics (RNAC) Stock Forecast & Price Target

RNAC Analyst Ratings

RNAC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cartesian Therapeutics

RNAC Analyst Recommendation Trends

RNAC Financial Forecast

RNAC Earnings Forecast

RNAC Sales Forecast

RNAC Stock Forecast FAQ

Detailed List of Analyst Forecasts